e1:BioAct
e2:CellLine

anti-proliferative;DU-145
anti-proliferative;HCT-116
anti-proliferative;HDFn
anti-proliferative;HT-29
anti-proliferative;DU-145
anti-proliferative;HCT-116
anti-proliferative;HDFn
anti-proliferative;HT-29
anti-proliferative;DU-145
anti-proliferative;HCT-116
anti-proliferative;HDFn
anti-proliferative;HT-29
anti-proliferative;DU-145
anti-proliferative;HCT-116
anti-proliferative;HDFn
anti-proliferative;HT-29
decrease cell viability;MCF-7
cytotoxic;HCT-116
cytotoxic;HL60
cytotoxic;HT-29
cytotoxic;MCF-7
cytotoxic;NCI-H226
cytotoxic;RPMI8226
cytotoxic;HCT-116
cytotoxic;HL60
cytotoxic;HT-29
cytotoxic;MCF-7
cytotoxic;NCI-H226
cytotoxic;RPMI8226
cytotoxic;HCT-116
cytotoxic;HL60
cytotoxic;HT-29
cytotoxic;MCF-7
cytotoxic;NCI-H226
cytotoxic;RPMI8226
cytotoxic;HCT-116
cytotoxic;HL60
cytotoxic;HT-29
cytotoxic;MCF-7
cytotoxic;NCI-H226
cytotoxic;RPMI8226
cytotoxic;HCT-116
cytotoxic;HL60
cytotoxic;HT-29
cytotoxic;MCF-7
cytotoxic;NCI-H226
cytotoxic;RPMI8226
cytotoxic;HCT-116
cytotoxic;HL60
cytotoxic;HT-29
cytotoxic;MCF-7
cytotoxic;NCI-H226
cytotoxic;RPMI8226
decrease cell viability MDA-MB-231;MDA-MB-231
growth inhibition and apoptosis in SMMC7721;SMMC7721
inhibited the proliferation;COLO 320 DM
inhibited the proliferation of MDA-MB-231;MDA-MB-231
inhibitory effects on Epstein-Barr virus early antigen;Epstein-Barr virus early antigen
suppress colonic ACF formation and crypt multiplicity;ACF
therapeutic efficacy against Ehrlich;Ehrlich
